Skip to Content
MilliporeSigma
  • Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment.

Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment.

Journal of neuro-oncology (2012-09-18)
Rintaro Hashizume, Ivan Smirnov, Sharon Liu, Joanna J Phillips, Jeanette Hyer, Tracy R McKnight, Michael Wendland, Michael Prados, Anu Banerjee, Theodore Nicolaides, Sabine Mueller, Charles D James, Nalin Gupta
ABSTRACT

Diffuse intrinsic pontine gliomas arise almost exclusively in children, and despite advances in treatment, the majority of patients die within 2 years after initial diagnosis. Because of their infiltrative nature and anatomic location in an eloquent area of the brain, most pontine gliomas are treated without a surgical biopsy. The corresponding lack of tissue samples has resulted in a limited understanding of the underlying genetic and molecular biologic abnormalities associated with pontine gliomas, and is a substantial obstacle for the preclinical testing of targeted therapeutic agents for these tumors. We have established a human glioma cell line that originated from surgical biopsy performed on a patient with a pontine glioma. To insure sustainable in vitro propagation, tumor cells were modified with hTERT (human telomerase ribonucleoprotein reverse transcriptase), and with a luciferase reporter to enable non-invasive bioluminescence imaging. The hTERT modified cells are tumorigenic in athymic rodents, and produce brainstem tumors that recapitulate the infiltrative growth of brainstem gliomas in patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
CWR-R1ca Human Prostate Cancer Cell Line, CWR-R1ca Human Prostate Cancer Cell Line is a valuable cell model for castration-recurrent prostate cancer studies.
Sigma-Aldrich
SF7761 Human DIPG H3.3-K27M Cell Line, SF7761 pediatric diffuse intrinsic pontine glioma (DIPG) cell line harbors the histone H3.3 Lys 27-to-methionine (K27M) mutation and can support research and drug development efforts targeting DIPG.